Prostate Cancer

African-American men with very low-risk prostate cancer being followed on active surveillance are at significantly higher risk for disease upgrading on subsequent biopsy compared to Caucasian men, according to analyses of prospectively collected data from the Johns Hopkins Active Surveillance registry.

A recent UCLA study suggests that physicians need to improve treatment counseling for patients with prostate cancer, a leading expert says.

The benefits of robot-assisted partial nephrectomy outweigh the health care and surgical costs, a new study found.

Earlier, more aggressive radiation therapy is recommended in prostate cancer patients with detectable PSA following radical prostatectomy, say the authors of a recently published study.

The muddy waters of patient selection and timing of post-prostatectomy radiation therapy may be clearer. Find out how.

A newer androgen receptor blocker significantly increases survival versus a first-generation agent in men with metastatic castration-resistant prostate cancer, data show.

A patient with an abnormal PSA level transferred to another physician's care and was never told of his result. Two and a half years later, a biopsy revealed Gleason 9 prostate cancer.

A large-scale study provides new evidence that targeted MRI ultrasound fusion prostate biopsy increases detection of high risk prostate cancers while decreasing detection of low-risk cancers. "More reliable diagnosis"

A newly published analysis “opens a huge opportunity for the discovery of new biomarkers” for multiple cancers, including aggressive prostate cancer, a leading urologic cancer expert says.

Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier, developer GenomeDx Biosciences reported.

While it is often difficult to defend a case involving the removal of an organ for cancer that is then determined to be cancer free, the added claim of lack of informed consent for the procedure does not aid the defense in these lawsuits.

A novel imaging technique may prove more effective than current magnetic resonance imaging approaches for localizing prostate tumors, researchers say.

A combination vaccine and androgen ablation therapy is showing promise in some patients with prostate cancer.

An advanced prostate cancer treatment protocol incorporating testosterone shows promise for treating the disease and reversing resistance to androgen deprivation therapy.

Advances in the diagnosis and treatment of prostate cancer are among the great medical accomplishments of the latter part of the 20th century and beginning of the 21st. Five-year survival rates for newly diagnosed loco-regional cancer advanced from 68% in 1975-’77 to 83% in 1987-’89 to nearly 100% in 2003-’09, according to the American Cancer Society. This victory, however impressive, is incomplete.

The addition of radiation treatment to hormone therapy reduces mortality in older men with locally advanced prostate cancer compared with hormone therapy alone, according to a recently published study in the Journal of Clinical Oncology.

A genomic test for prostate cancer was able to predict rapid metastatic disease in node-negative, high-risk men managed by radical prostatectomy without adjuvant therapy in a recently published study.

New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.

The rate of prostate biopsy declined steadily and significantly over a contemporary 10-year period, results of a retrospective longitudinal review of data from the Veterans Health Administration show.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some video resources on high-risk prostate cancer.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some recommended articles about the diagnosis and treatment of high-risk prostate cancer.

In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.

Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.

With emergence of new biomarker and tests, high-profile approvals of treatments for new indication, and the ongoing controversy surrounding PSA screening, prostate cancer remained very much in the urology headlines for 2014. Here are some of the most-read Urology Times articles on the disease.

Streamlined management for metastatic castration-resistant prostate cancer, greater autonomy for residents, and a better understanding of issues facing the VA are among changes urologists hope to see occur in 2015.